Unresectable or Metastatic MelanomaCobimetinib® is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations.
Histiocytic NeoplasmsCobimetinib® is indicated as monotherapy for the treatment of adult patients with histiocytic neoplasms.
FDA,2023.05